A Business at a Glance
0 of 5 daily views used (5 remaining). Sign up free for 10 daily views, or try AAPL for a full preview.
Celldex Therapeutics, Inc., which we refer to as “Celldex,” “we,” “us,” “our” or the “Company,” is a biopharmaceutical company dedicated to exploring the science of mast cell biology and developing therapeutic antibodies which have the ability to engage the human immune system and/or directly affect critical pathways to improve the lives of patients with severe inflammatory, allergic, autoimmune and other devastating diseases. Our drug candidates include monoclonal and bispecific antibodies designed to address mast cell mediated diseases for which available treatments are inadequate.
| Metric | TTM | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 |
|---|---|---|---|---|---|---|
| Revenue | 0 | - | - | - | - | - |
| Net Income | -259M | -259M | -158M | -141M | -112M | -71M |
| EPS | $-3.90 | $-3.90 | $-2.45 | $-2.92 | $-2.40 | $-1.64 |
| Free Cash Flow | -214M | -214M | -160M | -109M | -106M | -62M |
| ROIC | -45.3% | -40.6% | -21.1% | -33.0% | -34.4% | -16.8% |
| Gross Margin | - | - | - | - | - | - |
| Debt/Equity | 0.00 | 0.00 | 0.01 | 0.01 | 0.01 | 0.01 |
| Dividends/Share | $0.00 | - | - | - | - | - |
| Operating Income | -287M | -287M | -195M | -155M | -115M | -71M |
| Operating Margin | 0.0% | - | - | - | - | - |
| ROE | -49.1% | -40.6% | -21.1% | -33.0% | -34.4% | -16.8% |
| Shares Outstanding | 66M | 66M | 64M | 48M | 47M | 43M |
Celldex Therapeutics, Inc. passes 0 of 9 quality checks, indicating weak fundamentals.
Celldex Therapeutics, Inc. (CLDX) has a 5-year average return on invested capital (ROIC) of -29.2%. This is below average and may indicate limited pricing power.
Celldex Therapeutics, Inc. (CLDX) has a market capitalization of $2.2B. It is classified as a mid-cap stock.
Celldex Therapeutics, Inc. (CLDX) does not currently pay a regular dividend.
Celldex Therapeutics, Inc. (CLDX) operates in the In Vitro & In Vivo Diagnostic Substances industry, within the Healthcare sector.
Celldex Therapeutics, Inc. (CLDX) generated $-214 million in free cash flow in its most recent fiscal year. Negative free cash flow may indicate heavy investment or operational challenges.
Celldex Therapeutics, Inc. (CLDX) has a debt-to-equity ratio of 0.00. This indicates a conservatively financed balance sheet.
Celldex Therapeutics, Inc. (CLDX) reported earnings per share (EPS) of $-3.90 in its most recent fiscal year.
Celldex Therapeutics, Inc. (CLDX) has a return on equity (ROE) of -40.6%. A negative ROE may indicate losses or negative equity.
The Ledger Terminal provides 16 years of financial data for Celldex Therapeutics, Inc. (CLDX), sourced directly from SEC EDGAR filings. This includes income statements, balance sheets, cash flow statements, and key financial ratios.
Celldex Therapeutics, Inc. (CLDX) has a book value per share of $7.95, based on its most recent annual SEC filing.